Itraconazole therapy in aspergillosis: study in 49 patients

J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):607-14. doi: 10.1016/0190-9622(90)70263-h.

Abstract

Itraconazole, 200 to 400 mg once daily, was administered to 49 patients with different types of aspergillosis: pulmonary aspergilloma (14 patients), chronic necrotizing pulmonary aspergillosis (14), and invasive aspergillosis (21). Itraconazole was prescribed alone or in combination or after treatment with amphotericin B and flucytosine. Of 14 aspergilloma patients, 2 were cured and 8 had symptomatic improvement. In chronic necrotizing pulmonary aspergillosis, 7 of 14 patients were cured and 6 improved significantly. In invasive aspergillosis treatment failed in 6 patients and 15 were cured. Itraconazole can be an alternative to amphotericin B in the treatment of invasive aspergillosis and chronic necrotizing pulmonary aspergillosis. In aspergilloma itraconazole may be useful in inoperable cases.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy*
  • Chronic Disease
  • Drug Administration Schedule
  • Encephalitis / drug therapy
  • Female
  • Humans
  • Itraconazole
  • Ketoconazole / analogs & derivatives*
  • Ketoconazole / therapeutic use
  • Lung Diseases, Fungal / drug therapy
  • Male
  • Maxillary Sinusitis / drug therapy
  • Middle Aged
  • Recurrence

Substances

  • Antifungal Agents
  • Itraconazole
  • Ketoconazole